Panbela Therapeutics, Inc. Common Stock
PBLA
PBLA was delisted on the 6th of March, 2024.
6 hedge funds and large institutions have $945K invested in Panbela Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 11 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
11% more capital invested
Capital invested by funds: $854K → $945K (+$91.4K)
60% less funds holding
Funds holding: 15 → 6 (-9)
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.24M |
| 2 |
Walleye Capital
New York
|
+$958K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$650K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$37.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$175K |
| 2 |
ACM
Altium Capital Management
New York
|
-$148K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$72.1K |
| 4 |
HF
HRT Financial
New York
|
-$30K |
| 5 |
State Street
Boston,
Massachusetts
|
-$23.5K |
PBLA Hedge Fund Activity: Q2 2023 in Review
6 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q2 2023, worth a combined $945K — up 11% from $854K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PBLA and 2 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, adding an estimated $2.24M. The largest seller was CVI Holdings, exiting entirely with an estimated $175K sold.
- 6 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q2 2023, down from 15 in Q1 2023.
- Funds reported $945K of Panbela Therapeutics, Inc. Common Stock stock for Q2 2023, up 11% quarter-over-quarter.
- 2 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q2 2023 and 11 closed out, a net change of -9 holders.
- The largest Panbela Therapeutics, Inc. Common Stock buyer in Q2 2023 was Sabby Management, an estimated $2.24M added.
- The largest Panbela Therapeutics, Inc. Common Stock seller in Q2 2023 was CVI Holdings, an estimated $175K sold.
Based on aggregated 13F filings for Q2 2023.